CPRIT awards UT MD Anderson nearly $29 million for cancer research, prevention and faculty recruitment

The University of Texas MD Anderson Cancer Center today was awarded nearly $29 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of cancer research efforts, prevention programs and faculty recruitment.

“We are truly grateful for CPRIT’s continued funding support, which accelerates the foundational discoveries, translational research and prevention initiatives that advance our mission to end cancer,” said Albert Koong, M.D., Ph.D., chief scientific officer. “These investments result in breakthroughs that transform how we are able to prevent cancer and care for patients across Texas and around the world.”

Since its inception, CPRIT has awarded over $4 billion in grants for cancer research. UT MD Anderson investigators have received more than $774 million, approximately 19% of the total awards. CPRIT award recipients include 151 academic institutions, non-profit organizations and private companies located in Texas. The research and prevention efforts funded by CPRIT advance the health of Texans, the research superiority of the state, the life science infrastructure and the Texas economy.

Academic research awards to UT MD Anderson include:

  •  Targeting nuclear envelope integrity as a therapeutic vulnerability in pediatric high-grade gliomas (Jian Hu, Ph.D., Cancer Biology) - $1,200,000
  • WAVE – Writing for Awareness, Voice, and Empowerment (Qian Lu, M.D., Ph.D., Health Disparities Research) - $1,200,000
  • Targeting hyperacetylation in pediatric diffuse midline glioma using oncolytic adenoviruses and P300 inhibitors (Juan Fueyo, M.D., Neuro-Oncology) - $1,198,124
  • Mechanometabolism and malignant progression of pancreatic cancer precursor lesions (Eugene Koay, M.D., Ph.D., GI Radiation Oncology) - $1,049,972
  • Multi-scale understanding of pollutant burden impact on lung adenocarcinoma risk and microenvironment alteration (Lulu Shang, Ph.D., Biostatistics) - $1,048,567
  • Elucidating the molecular identities and clonal dynamics of MRD using semi-supervised machine learning (Pavan Bachireddy, M.D., Hematopoietic Biology & Malignancy) - $1,048,443
  • Spatially fractionated radiotherapy using alpha particles to sensitize immunologically cold pancreatic cancer to immunotherapy (Gabriel Sawakuchi, Ph.D., Radiation Physics) - $900,000
  • Targeting aggressive variants of renal cell carcinoma through in vivo functional genomics (Giannicola Genovese, M.D., Ph.D., Genitourinary Medical Oncology) - $900,000
  • Targeting replication fork protection to overcome therapy resistance in BRCA cancers (Katharina Schlacher, Ph.D., Cancer Biology) - $900,000
  •  Urine proteomics for evaluation and diagnosis of immune checkpoint toxicity (U_PREDICT) (Jamie Lin, M.D., Emergency Medicine) - $900,000
  • Sugar-sweetened beverages drive colorectal cancer progression through the gut microbiome (Jihye Yun, Ph.D., Genetics) - $900,000
  • Obesity-linked drivers of prostate cancer subtypes (Daniel Frigo, Ph.D., Cancer Systems Imaging) - $900,000
  • B cells as predictive biomarkers for the risk of immune checkpoint therapy-associated colitis (Roza Nurieva, Ph.D., Immunology) - $900,000
  • Immune-based targeting of ALPP and other Kras inhibitor-induced cell surface targets in treatment-resistant NSCLC (John Heymach, M.D., Ph.D., Thoracic/Head and Neck Medical Oncology) - $899,997
  • Validating functional receptors of opioids on immune cells (Yu Leo Lei, D.D.S., Ph.D., Head and Neck Surgery) - $899,994
  • Chromosomal instability drives myeloid and gamma delta T cell immune suppression in MSS colorectal cancer (Ronald DePinho, M.D., Cancer Biology) - $899,994
  • MUC13-targeted theranostics for colorectal cancer (Henry Manning, Ph.D., Nuclear Medicine) - $899,994
  • Tumor progenitors and their proinflammatory cues for lung cancer interception (Humam Kadara, Ph.D., Translational Molecular Pathology) - $899,776
  • Targeting centromeric RNA-induced chromosomal instability and RNA-sensing pathways in cGAS-deficient tumors (Timothy Yap, M.B.B.S., Ph.D., Investigational Cancer Therapeutics) - $899,619
  • Non-invasive physiologic predictors of aggressiveness in renal cell carcinoma (Ivan Pedrosa, M.D., Ph.D., Abdominal Imaging) - $899,475
  • Predictive multimodal mapping of language-eloquent brain to improve surgical planning and postoperative outcomes in glioma patients (Ho-Ling Anthony Liu, Ph.D., Imaging Physics) - $899,343
  • Mitochondrial stress-induced survival dependencies as therapeutic targets in T-ALL (Deepa Sampath, Ph.D., Hematopoietic Biology & Malignancy) - $894,993
  • Evaluating NK cell fitness to overcome disease progression through therapeutic NK-cell modulation in chronic myelomonocytic leukemia (Guillermo Montalban-Bravo, M.D., Leukemia) - $888,454
  • Rewiring the ovarian tumor microenvironment through dual CD5L-VEGF targeting (Anil Sood, M.D., Gynecologic Oncology and Reproductive Medicine) - $886,115
  • Defining the role of mitochondrial genetics in stem cell fitness and clonal evolution (Koichi Takahashi, M.D., Ph.D., Leukemia) - $879,738

Prevention awards to UT MD Anderson include:

  • Improving lung cancer screening uptake through integrated mammography-based navigation (Banu Arun, M.D., Breast Medical Oncology) - $1,499,556
  • CATALYST: An implementation support program to increase cervical cancer screening in federally qualified health centers (Jane Montealegre, Ph.D., Behavioral Science) - $1,498,619

In addition, CPRIT awarded $2 million to support the recruitment of a first-time, tenure-track faculty member.

 

We are truly grateful for CPRIT’s continued funding support, which accelerates the foundational discoveries, translational research and prevention initiatives that advance our mission to end cancer. These investments result in breakthroughs that transform how we are able to prevent cancer and care for patients across Texas and around the world.

Albert Koong, M.D., Ph.D.

Chief Scientific Officer